{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:52:34Z","timestamp":1792785154648,"version":"4.5.0"},"reference-count":86,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"name":"German Research Foundation, DFG","award":["RO957\/13-1, RO3714\/4-2"],"award-info":[{"award-number":["RO957\/13-1, RO3714\/4-2"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major global health challenge, largely driven by the increasing prevalence of obesity and type 2 diabetes mellitus. The disease spectrum ranges from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH) with progressive fibrosis. Advanced fibrosis substantially increases the risk of cirrhosis, hepatocellular carcinoma, and cardiovascular complications, thereby contributing significantly to morbidity and mortality.Although lifestyle modification remains the cornerstone of therapy, pharmacological treatment is gaining importance in patients with progressive disease or high-risk profiles. Advances in the understanding of MASLD pathophysiology have enabled the development of targeted therapies addressing hepatic lipid accumulation, insulin resistance, inflammation, and fibrogenesis. Promising clinical data have been reported for resmetirom, semaglutide, tirzepatide, survodutide, lanifibranor, and fibroblast growth factor-21 analogues including efruxifermin, pegozafermin, and efimosfermin.This review summarises current and emerging diagnostic and therapeutic strategies and provides practical guidance for clinical management. In addition, a structured treatment algorithm for non-cirrhotic MASLD (F0\u2013F3), restricted to therapies currently available in Europe and stratified according to diabetes status and fibrosis stage, is proposed as an evidence-based tool for routine clinical practice.<\/jats:p>","DOI":"10.1055\/a-2894-7628","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:31:01Z","timestamp":1790202661000},"page":"1239-1249","source":"Crossref","is-referenced-by-count":0,"title":["MASLD: Established Knowledge and Emerging Directions \u2013 Guideline Updates"],"prefix":"10.1055","volume":"64","author":[{"given":"Elke","family":"Roeb","sequence":"additional","affiliation":[{"name":"Justus Liebig University Giessen, Germany","place":["Giessen"],"department":["Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[{"name":"University of W\u00fcrzburg, Germany","place":["W\u00fcrzburg"],"department":["Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1055\/a-2309-6052","article-title":"Amendment \u201cNeue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion -assoziierte steatotische Lebererkrankung)\u201d zur S2k-Leitlinie \u201cNicht-alkoholische Fettlebererkrankung\u201d (v. 2.0\/April 2022) der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)","volume":"62","author":"E Roeb","year":"2024","journal-title":"Z Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70017","article-title":"MetALD: New Perspectives on an Old Overlooked Disease","volume":"45","author":"G Ayares","year":"2025","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/apt.17846","article-title":"Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"R Loomba","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"ZM Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00428-011-1066-1","article-title":"Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease","volume":"458","author":"A Tannapfel","year":"2011","journal-title":"Virchows Arch"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review","volume":"335","author":"H Tilg","year":"2026","journal-title":"Jama"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/17474124.2025.2545812","article-title":"Food insecurity is an emerging risk factor for liver disease: a scoping review","volume":"19","author":"A Lonardo","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/17474124.2025.2600386","article-title":"From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"G Forcina","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000519611","article-title":"Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review","volume":"38","author":"E Roeb","year":"2022","journal-title":"Visc Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2020-323202","article-title":"From the origin of NASH to the future of metabolic fatty liver disease","volume":"70","author":"A Geier","year":"2021","journal-title":"Gut"},{"key":"ref12","first-page":"71","article-title":"Fructose Consumption-Free Sugars and Their Health Effects","volume":"118","author":"S Stricker","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70132","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances","volume":"8","author":"DM Miller","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","article-title":"Food inequity and insecurity and MASLD: burden, challenges, and interventions","volume":"21","author":"S Zelber-Sagi","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis","volume":"26","author":"P Hoffmann","year":"2020","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.15698\/cst2025.06.305","article-title":"Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review","volume":"9","author":"K Burger","year":"2025","journal-title":"Cell Stress"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.634344","article-title":"Fructose and Non-Alcoholic Steatohepatitis","volume":"12","author":"E Roeb","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3945\/ajcn.114.086314","article-title":"Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis","volume":"100","author":"M Chung","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ejcn.2014.8","article-title":"Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials","volume":"68","author":"S Chiu","year":"2014","journal-title":"Eur J Clin Nutr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1053\/j.gastro.2013.07.012","article-title":"No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men","volume":"145","author":"RD Johnston","year":"2013","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v18.i2.111962","article-title":"Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals","volume":"18","author":"GS Farina","year":"2026","journal-title":"World J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/apt.70639","article-title":"Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease \u2013 Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies","volume":"63","author":"N Alkhouri","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apt.70376","article-title":"Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH","volume":"63","author":"LM Nitze","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1055\/a-1880-2283","article-title":"Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) \u2013 April 2022 \u2013 AWMF-Registernummer: 021\u2013025","volume":"60","author":"E Roeb","year":"2022","journal-title":"Z Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70225","article-title":"Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel","volume":"45","author":"Y Kim","year":"2025","journal-title":"Liver Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00292-010-1274-5","article-title":"Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines","volume":"31","author":"A Tannapfel","year":"2010","journal-title":"Pathologe"},{"issue":"03","key":"ref27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"EASL-EASD-EASO","year":"2024","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"PS Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"P Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101011","article-title":"Impact of age on NIS2+ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH","volume":"6","author":"QM Anstee","year":"2024","journal-title":"JHEP Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease","volume":"331","author":"H Lin","year":"2024","journal-title":"Jama"},{"key":"ref32","first-page":"386","article-title":"Amendment \u201cResmetirom\u201d to the S2k guideline \u201cMetabolic Liver Diseases\u201d (formerly \u201cNon-Alcoholic Fatty Liver Disease\u201d v.2.0\/April 2022) of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) (Version 2.3)","volume":"64","author":"E Roeb","year":"2026","journal-title":"Z Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"VL Chen","year":"2025","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.cgh.2025.02.014","article-title":"Non-invasive Identification of Metabolic Dysfunction-associated Steatotic Liver Disease Patients Eligible for Resmetirom Treatment","volume":"23","author":"K John","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","author":"Liver EAftSot","year":"2021","journal-title":"J Hepatol"},{"key":"ref36","article-title":"Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes","author":"T Vidal-Tr\u00e9can","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","article-title":"Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications","volume":"21","author":"J Boursier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/dom.16142","article-title":"Diagnostic accuracy of Agile-4 score for liver cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease. A systematic review and meta-analysis of diagnostic test accuracy studies","volume":"27","author":"K Malandris","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112608","article-title":"Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies","volume":"12","author":"D Gosalia","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"SA Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"S Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jhep.2025.01.014","article-title":"Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"TC Yip","year":"2025","journal-title":"J Hepatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgh.14311","article-title":"Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness","volume":"34","author":"JC Chow","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/HEP.0000000000001190","article-title":"Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis","volume":"82","author":"MG Indre","year":"2025","journal-title":"Hepatology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3390\/diagnostics15131598","article-title":"Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis","volume":"15","author":"MP Wilson","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70281","article-title":"Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments","volume":"45","author":"M Franck","year":"2025","journal-title":"Liver International"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16240","article-title":"Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD","volume":"45","author":"Y Vali","year":"2025","journal-title":"Liver Int"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1111\/jgh.70086","article-title":"Liver Fat Quantification and Steatosis Grading in Fatty Liver Disease by Magnetic Resonance Imaging: Systematic Review and Meta-Analysis","volume":"40","author":"LI Al-Huneidi","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001617","article-title":"Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study","author":"ZM Younossi","year":"2025","journal-title":"Hepatology"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/01939459251400493","article-title":"Effect of E-Health-Assisted Lifestyle Interventions on Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, Formerly NAFLD): A Meta-Analysis","author":"F Celik","year":"2026","journal-title":"West J Nurs Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/nu18010028","article-title":"The Impact of the Mediterranean Diet, Physical Activity, and Nutrition Education on Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Review","volume":"18","author":"M Bernardino","year":"2025","journal-title":"Nutrients"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12876-025-04535-1","article-title":"Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis","volume":"26","author":"J Zou","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref53","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2025.112975","article-title":"Mediterranean diet for the management of pre-existing metabolic diseases: Evidence from a systematic review and meta-analysis featured in the Italian national guidelines \u201cLa Dieta Mediterranea\u201d","volume":"142","author":"G Muscogiuri","year":"2026","journal-title":"Nutrition"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101903","article-title":"Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group","volume":"30","author":"LA Diaz","year":"2025","journal-title":"Ann Hepatol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"SA Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","author":"SA Harrison","year":"2023","journal-title":"Nat Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"AJ Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"PN Newsome","year":"2025","journal-title":"J Clin Invest"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"M Souza","year":"2025","journal-title":"Hepatology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"R Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"R Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101450","article-title":"PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feeding","volume":"7","author":"L Jegodzinski","year":"2025","journal-title":"JHEP Rep"},{"key":"ref63","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70164","article-title":"Deep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease","volume":"45","author":"Y Chen","year":"2025","journal-title":"Liver Int"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70461","article-title":"Ninety-Day Readmission and Morbidity Following Liver Transplantation for MASLD","volume":"40","author":"Z Leslie","year":"2026","journal-title":"Clin Transplant"},{"key":"ref65","doi-asserted-by":"crossref","DOI":"10.2196\/11250","article-title":"Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study","volume":"21","author":"D Pfirrmann","year":"2019","journal-title":"J Med Internet Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"N Fujiwara","year":"2018","journal-title":"J Hepatol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","article-title":"Type 2 Diabetes and Metformin Use Associate With\u00a0Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis","volume":"19","author":"E Vilar-Gomez","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.cgh.2020.08.026","article-title":"Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis","volume":"19","author":"DE Kaplan","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"X Zhang","year":"2014","journal-title":"Hepatology"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH\/NASH and Moderate to Noncirrhotic Advanced Fibrosis","volume":"22","author":"M Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MEG.0000000000002901","article-title":"Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis","volume":"37","author":"L Abbasi","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"111","DOI":"10.14744\/hf.2025.2025.0050","article-title":"Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven MASLD cohort","volume":"6","author":"E Kaya","year":"2025","journal-title":"Hepatol Forum"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","article-title":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review","volume":"19","author":"V Cunha","year":"2020","journal-title":"Ann Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1111\/liv.13872","article-title":"Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes","volume":"38","author":"CH Tseng","year":"2018","journal-title":"Liver Int"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12885-025-14299-2","article-title":"Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis","volume":"25","author":"N Hosseinkhan","year":"2025","journal-title":"BMC Cancer"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-25-0287","article-title":"Statin use and risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A national retrospective cohort study","author":"SG Kim","year":"2026","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2024-334591","article-title":"Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies","volume":"74","author":"C Celsa","year":"2025","journal-title":"Gut"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes","volume":"167","author":"L Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/HEP.0000000000000404","article-title":"SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong","volume":"78","author":"CH Lee","year":"2023","journal-title":"Hepatology"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2022.03.010","article-title":"An elevated FIB-4 score is associated with an increased incidence of liver cancer: A longitudinal analysis among 248,224 outpatients in Germany","volume":"168","author":"SH Loosen","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2021.08.030","article-title":"An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD","volume":"76","author":"SH Loosen","year":"2022","journal-title":"J Hepatol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cgh.2023.11.020","article-title":"Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis","volume":"22","author":"BV John","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1136\/gutjnl-2025-334981","article-title":"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"JC Lai","year":"2025","journal-title":"Gut"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/a-1986-7676","article-title":"Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany \u2013 First data from the German NAFLD-Registry","volume":"61","author":"A Geier","year":"2023","journal-title":"Z Gastroenterol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"KP Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1055\/a-2592-6109","article-title":"Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry","volume":"63","author":"EK Messer","year":"2025","journal-title":"Z Gastroenterol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2894-7628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:31:14Z","timestamp":1790202674000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2894-7628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":86,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2894-7628","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}